Noveome Biotherapeutics, founded to pioneer regenerative therapies, is a clinical-stage company dedicated to the repair of inflamed or damaged tissues. Their core mission is to develop breakthrough treatments that harness biologic components to promote anti-inflammatory, neuroprotective, anti-apoptotic, and vascular integrity preservative properties. Their flagship product, ST266, is a multi-targeted secretome containing hundreds of biologically active proteins and factors essential for neuroprotection, inflammation modulation, cell recovery, and healing. Noveome primarily focuses on addressing conditions such as necrotizing enterocolitis in neonates.

Notable achievements of Noveome Biotherapeutics include receiving rare pediatric disease designation and orphan drug designation for their treatment of necrotizing enterocolitis. The company has garnered attention from key investors and industry experts due to its innovative approach and potential to simulate natural healing processes. Through its advanced biologic therapies, Noveome aims to make a significant impact on regenerative medicine and improve outcomes for patients with severe tissue damage and inflammation.